Skip to main content
Open Access Publications from the University of California


UC San Francisco Previously Published Works bannerUCSF

Efficacy and safety of memantine in children with autism spectrum disorder: Results from three phase 2 multicenter studies.

  • Author(s): Hardan, Antonio Y
  • Hendren, Robert L
  • Aman, Michael G
  • Robb, Adelaide
  • Melmed, Raun D
  • Andersen, Kristen A
  • Luchini, Rachel
  • Rahman, Rezwanur
  • Ali, Sanjida
  • Jia, X Daniel
  • Mallick, Madhuja
  • Lateiner, Jordan E
  • Palmer, Robert H
  • Graham, Stephen M
  • et al.

Three phase 2 trials were conducted to assess the efficacy and long-term safety of weight-based memantine extended release (ER) treatment in children with autism spectrum disorder. MEM-MD-91, a 50-week open-label trial, identified memantine extended-release treatment responders for enrollment into MEM-MD-68, a 12-week randomized, double-blind, placebo-controlled withdrawal trial. MEM-MD-69 was an open-label extension trial in which participants from MEM-MD-68, MEM-MD-91, and open-label trial MEM-MD-67 were treated ⩽48 weeks with memantine extended release. In MEM-MD-91, 517 (59.6%) participants were confirmed Social Responsiveness Scale responders at week 12; mean Social Responsiveness Scale total raw scores improved two to three times a minimal clinically important difference of 10 points. In MEM-MD-68, there was no difference between memantine and placebo on the primary efficacy parameter, the proportion of patients with a loss of therapeutic response (defined as ⩾10-point increase from baseline in Social Responsiveness Scale total raw score). MEM-MD-69 exploratory analyses revealed mean standard deviation improvement in Social Responsiveness Scale total raw score of 32.4 (26.4) from baseline of the first lead-in study. No new safety concerns were evident. While the a priori-defined efficacy results of the double-blind trial were not achieved, the considerable improvements in mean Social Responsiveness Scale scores from baseline in the open-label trials were presumed to be clinically important.

Many UC-authored scholarly publications are freely available on this site because of the UC's open access policies. Let us know how this access is important for you.

Main Content
Current View